» Articles » PMID: 22694276

Molecular Pathways in Colorectal Cancer

Overview
Specialty Gastroenterology
Date 2012 Jun 15
PMID 22694276
Citations 115
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is the second most common newly diagnosed cancer and accounts for the second highest number of cancer related deaths in Australia, the third worldwide and of increasing importance in Asia. It arises through cumulative effects of inherited genetic predispositions and environmental factors. Genomic instability is an integral part in the transformation of normal colonic or rectal mucosa into carcinoma. Three molecular pathways have been identified: these are the chromosomal instability (CIN), the microsatellite instability (MSI), and the CpG Island Methylator Phenotype (CIMP) pathways. These pathways are not mutually exclusive, with some tumors exhibiting features of multiple pathways. Germline mutations are responsible for hereditary CRC syndromes (accounting for less than 5% of all CRC) while a stepwise accumulation of genetic and epigenetic alterations results in sporadic CRC. This review aims to discuss the genetic basis of hereditary CRC and the different pathways involved in the process of colorectal carcinogenesis.

Citing Articles

Linking microRNA to metabolic reprogramming and gut microbiota in the pathogenesis of colorectal cancer (Review).

Bin Wan Mohd Nor W, Kwong S, Fuzi A, Said N, Jamil A, Lee Y Int J Mol Med. 2025; 55(3).

PMID: 39820715 PMC: 11759585. DOI: 10.3892/ijmm.2025.5487.


Unveiling STRs instability in a colorectal cancer FFPE sample: a case report.

Soldati G, Saccardo C, Raniero D, De Leo D, Turrina S Int J Legal Med. 2024; 139(1):61-65.

PMID: 39377931 PMC: 11732918. DOI: 10.1007/s00414-024-03341-w.


Could Flow Cytometry Provide New Prognostic Markers in Colorectal Cancer?.

Georvasili V, Markopoulos G, Lampri E, Lianos G, Vartholomatos G, Mitsis M J Clin Med. 2024; 13(16).

PMID: 39200895 PMC: 11355755. DOI: 10.3390/jcm13164753.


Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer.

Fan W, Su F, Zhang Y, Zhang X, Du Y, Gao Y Biomark Res. 2024; 12(1):89.

PMID: 39183366 PMC: 11346251. DOI: 10.1186/s40364-024-00640-7.


Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions.

Yan L, Shi J, Zhu J Discov Oncol. 2024; 15(1):294.

PMID: 39031216 PMC: 11265098. DOI: 10.1007/s12672-024-01163-1.